Pharmacy Pearls: GOLD Guideline Updates

December 29th, 2023 | Asthma/COPD•Pharmacy Pearls

In this two-page edition of Pharmacy Pearls, you will find a review of the 2023 updates to the GOLD Guidelines for the treatment of COPD. There are several notable changes from previous versions of the guidelines, including a modification to the symptom/exacerbation risk assessment and the elimination of ICS+LABA as a routine treatment recommendation (other than if the patient is currently well-controlled on that regimen). There is also a review of all commercially available inhalers approved for COPD, including brand and generic names and typical dosing.

As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.

Taking too long?

Reload document

Open in new tab

Download PDF

135 Corporate Woods, Suite 320
Rochester, New York 14623-1466

Phone: (585) 758-7823
Fax: (585) 424-1268

Website by:

This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

Pharmacy Pearls: GOLD Guideline Updates

Pharmacy Pearls: GOLD Guideline Updates

GENERAL COVID-19 INFORMATION